Victory Capital Management Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Victory Capital Management Inc. decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 86.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 174,397 shares of the biopharmaceutical company's stock after selling 1,083,811 shares during the quarter. Victory Capital Management Inc. owned approximately 0.06% of Amicus Therapeutics worth $1,643,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. KBC Group NV boosted its stake in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period. Legacy Capital Group California Inc. boosted its stake in shares of Amicus Therapeutics by 20.2% during the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 3,900 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $55,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Amicus Therapeutics by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock worth $597,000 after buying an additional 6,314 shares during the period. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Amicus Therapeutics by 46.3% during the third quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 6,484 shares during the period.

Remove Ads

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.07 during midday trading on Friday, reaching $9.01. 2,928,681 shares of the company traded hands, compared to its average volume of 2,390,593. The firm's 50 day simple moving average is $9.35 and its two-hundred day simple moving average is $10.08. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The firm has a market cap of $2.77 billion, a PE ratio of -50.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.